This website uses technologies to collect information on your browser, mostly in the form of cookies to allow the site to work as expected and to give you a more personalized experience. For more information, visit our privacy policy. Cookie Policy

REJECTALLOW

Metastatic Progression in Uveal Melanoma

It’s not just about what’s visible now, but what could be coming.¹

Early recognition of metastasis matters.¹

Risk Stratification today can define tomorrow’s path forward.^2-5

Gene Expression Profiling MAY inform future decisions.^3,4

Shared planning leads to optimal patient care.²

Early referral starts with you.

Metastatic Progression in Uveal Melanoma

It’s not just about what’s visible now, but what could be coming.¹

Early recognition of metastasis matters.¹

Risk Stratification today can define tomorrow’s path forward.^2-5

Gene Expression Profiling MAY inform future decisions.^3,4

Shared planning leads to optimal patient care.²

Early referral starts with you.

Historically, metastatic disease in uveal melanoma has been associated with poor outcomes—but today, early action and informed planning could help shape the path forward.^1-3

Eyes on experience:

UM metastasis

Eyes on experience:

GEP/PRAME

Eyes on experience:

Metastatic risk

UM Metastasis

METASTASIS IS COMMON^1,2—DON’T LET IT GO UNNOTICED

Testing and surveillance are the first steps in staying ahead of mUM^2-5:

UP
TO50%

of patients with uveal melanoma will develop metastatic disease^1,2

20%-70%

widely varied metastatic risk depending on disease classification and individual prognosis factors¹

IN90%OF CASES

the liver is the first site of metastasis²

Don’t wait for symptoms. TESTING AND SURVEILLANCE should start early and be risk-informed.^2-5

GEP/PRAME

Assist in shaping future care strategies with gene expression profiling AND PRAME TESTING^3-5

In addition to tumor size and location, the genetic profile offers important information that can help assess metastatic risk and support informed decisions about future treatment options.^2-4

Gene expression profiling (GEP) can reliably classify metastatic risk based on the tumor’s molecular profile.^3,4

The addition of Preferentially Expressed Antigen in MElanoma (PRAME) testing to the GEP assay can provide more precise prognostic information and further refine the risk categories.^3-5

CLASS 1A OR CLASS 1 PRAME (-)Low metastatic risk

CLASS 1B OR CLASS 1 PRAME (+)Medium metastatic risk

Class 2High metastatic risk

GEP AND PRAME TESTING can inform risk-adjusted patient management.^3-5

FACTOR HLA BLOOD TESTING INTO THE LONG-TERM MANAGEMENT OF UM/mUM PATIENTS

When considering long-term treatment plans for UM patients at higher risk of metastasis, HLA testing may provide useful information.³ Genetic testing can determine treatment eligibility and support timely care decisions.³

Key points about HLA testing:

HLA status is generally confirmed by a high‑resolution blood test (resolved to the fourth digit), which provides detailed allele group and the specific HLA protein^6,7
Tumor biopsy is not recommended for determining HLA status, as chromosomal changes in the tumor may affect results^8,9

HLA Status can be assessed by a blood test at any time.¹⁰

Metastatic Risk

Risk stratification could help
empower precision imaging surveillance^3,11

Imaging surveillance tailored to a patient’s metastatic risk may enable earlier detection of metastasis in UM.³ Therefore, the frequency of imaging should be defined according to each patient’s metastatic risk, which may enable timely identification of metastasis and more personalized follow-up care.³

RISK-BASED FRAMEWORK GUIDES FREQUENCY OF SURVEILLANCE IMAGING FOR mUM^3,11

LOW RISK

45^% of tumors

12 months for 5 years, or as clinically directed.

MEDIUM RISK

20^% of tumors

6-12 months for 10 years, then as clinically directed.

HIGH RISK

35^% of tumors

3-6 months for 5 years, then every 6-12 months for 6-10 years, then as clinically directed.

Options include contrast-enhanced magnetic resonance imaging (MRI) or ultrasound imaging of the liver, with modality preference determined by expertise at the treating institution; additional modalities may include chest/abdominal/pelvic computed tomography (CT) with contrast, or chest x-ray.³

Coordinated insight helps determine when and how to screen.²

Resources

Explore resources and clinical insights

All Eyes on Metastatic Risk in Uveal Melanoma
Hear leading ocular and medical oncologists discuss real-world approaches to risk assessment, surveillance, and long-term care in this expert roundtable series.

→ Upcoming roundtables and expert insights COMING SOON

Eyes on experience:

UM metastasis

Eyes on experience:

GEP/PRAME

Eyes on experience:

Metastatic risk

MEDICAL INFORMATION CONTACT EMAIL

HLA, human leukocyte antigen; mUM, metastatic uveal melanoma; UM, uveal melanoma.

References: 1. Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758834018757175. doi:10.1177/1758834018757175 2. Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38-44. doi:10.1136/bjophthalmol-2016-309034 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Uveal V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 18, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596-1603. doi:10.1016/j.ophtha.2012.02.017 5. Harbour JW, Correa ZM, Schefler AC, et al. 15-Gene expression profile and PRAME as integrated prognostic test for uveal melanoma: first report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1). J Clin Oncol. 2024;42(28):3319-3329. doi:10.1200/JCO.24.00447 6. Tiercy JM. How to select the best available related or unrelated donor of hematopoietic stem cells? Haematologica. 2016;101(6):680-687. doi:10.3324/haematol.2015.141119 7. Nunes E, Heslop H, Fernandez-Vina M, et al. Definitions of histocompatibility typing terms. Blood. 2011;118(23):e180-e183. doi:10.1182/blood-2011-05-353490 8. Fonseca C, Pinto-Proença R, Bergeron S, et al. Intratumoral heterogeneity in uveal melanoma. Ocul Oncol Pathol. 2021;7:17-25. doi:10.1159/000508517 9. Metzelaar-Blok JA, Jager MJ, Moghaddam PH, et al. Frequent loss of heterozygosity on chromosome 6p in uveal melanoma. Hum Immunol. 1999;60:962-969. doi:10.1016/s0198-8859(99)00067-1 10. Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 2007;48(1):11-23. doi:10.3349/ymj.2007.48.1.11 11. Carvajal RD, Sacco JJ, Jager MJ, et al. Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023;20(2):99-115. doi:10.1038/s41571-022-00714-1

Metastatic Progression in Uveal Melanoma

It’s not just about what’s visible now, but what could be coming.¹

Early recognition of metastasis matters.¹

Risk Stratification today can define tomorrow’s path forward.^2-5

Gene Expression Profiling MAY inform future decisions.^3,4

Shared planning leads to optimal patient care.²

Early referral starts with you.

Metastatic Progression in Uveal Melanoma

It’s not just about what’s visible now, but what could be coming.¹

Early recognition of metastasis matters.¹

Risk Stratification today can define tomorrow’s path forward.^2-5

Gene Expression Profiling MAY inform future decisions.^3,4

Shared planning leads to optimal patient care.²

Early referral starts with you.

Historically, metastatic disease in uveal melanoma has been associated with poor outcomes—but today, early action and informed planning could help shape the path forward.^1-3

Eyes on experience:

Eyes on experience:

Eyes on experience:

METASTASIS IS COMMON^1,2—DON’T LET IT GO UNNOTICED

Testing and surveillance are the first steps in staying ahead of mUM^2-5:

Don’t wait for symptoms. TESTING AND SURVEILLANCE should start early and be risk-informed.^2-5

Assist in shaping future care strategies with gene expression profiling AND PRAME TESTING^3-5

In addition to tumor size and location, the genetic profile offers important information that can help assess metastatic risk and support informed decisions about future treatment options.^2-4

GEP AND PRAME TESTING can inform risk-adjusted patient management.^3-5

FACTOR HLA BLOOD TESTING INTO THE LONG-TERM MANAGEMENT OF UM/mUM PATIENTS

When considering long-term treatment plans for UM patients at higher risk of metastasis, HLA testing may provide useful information.³ Genetic testing can determine treatment eligibility and support timely care decisions.³

Key points about HLA testing:

HLA Status can be assessed by a blood test at any time.¹⁰

Risk stratification could help
empower precision imaging surveillance^3,11

Coordinated insight helps determine when and how to screen.²

Explore resources and clinical insights

All Eyes on Metastatic Risk in Uveal Melanoma
Hear leading ocular and medical oncologists discuss real-world approaches to risk assessment, surveillance, and long-term care in this expert roundtable series.

Eyes on experience:

Eyes on experience:

Eyes on experience:

Want to be part of the conversation?

If you have questions, please click below to contact the medical information team:

Metastatic Progression in Uveal Melanoma

It’s not just about what’s visible now, but what could be coming.¹

Early recognition of metastasis matters.¹

Risk Stratification today can define tomorrow’s path forward.2-5

Gene Expression Profiling MAY inform future decisions.3,4

Shared planning leads to optimal patient care.2

Early referral starts with you.

Metastatic Progression in Uveal Melanoma

It’s not just about what’s visible now, but what could be coming.1

Early recognition of metastasis matters.1

Risk Stratification today can define tomorrow’s path forward.2-5

Gene Expression Profiling MAY inform future decisions.3,4

Shared planning leads to optimal patient care.2

Early referral starts with you.

Historically, metastatic disease in uveal melanoma has been associated with poor outcomes—but today, early action and informed planning could help shape the path forward.1-3

Eyes on experience:

Eyes on experience:

Eyes on experience:

METASTASIS IS COMMON1,2—DON’T LET IT GO UNNOTICED

Testing and surveillance are the first steps in staying ahead of mUM2-5:

Don’t wait for symptoms. TESTING AND SURVEILLANCE should start early and be risk-informed.2-5

Assist in shaping future care strategies with gene expression profiling AND PRAME TESTING3-5

In addition to tumor size and location, the genetic profile offers important information that can help assess metastatic risk and support informed decisions about future treatment options.2-4

GEP AND PRAME TESTING can inform risk-adjusted patient management.3-5

FACTOR HLA BLOOD TESTING INTO THE LONG-TERM MANAGEMENT OF UM/mUM PATIENTS

When considering long-term treatment plans for UM patients at higher risk of metastasis, HLA testing may provide useful information.3 Genetic testing can determine treatment eligibility and support timely care decisions.3

Key points about HLA testing:

HLA Status can be assessed by a blood test at any time.10

Risk stratification could help empower precision imaging surveillance3,11

Coordinated insight helps determine when and how to screen.2

Explore resources and clinical insights

All Eyes on Metastatic Risk in Uveal MelanomaHear leading ocular and medical oncologists discuss real-world approaches to risk assessment, surveillance, and long-term care in this expert roundtable series.

Eyes on experience:

Eyes on experience:

Eyes on experience:

Want to be part of the conversation?

If you have questions, please click below to contact the medical information team:

Risk Stratification today can define tomorrow’s path forward.^2-5

Gene Expression Profiling MAY inform future decisions.^3,4

Shared planning leads to optimal patient care.²

It’s not just about what’s visible now, but what could be coming.¹

Early recognition of metastasis matters.¹

Risk Stratification today can define tomorrow’s path forward.^2-5

Gene Expression Profiling MAY inform future decisions.^3,4

Shared planning leads to optimal patient care.²

Historically, metastatic disease in uveal melanoma has been associated with poor outcomes—but today, early action and informed planning could help shape the path forward.^1-3

METASTASIS IS COMMON^1,2—DON’T LET IT GO UNNOTICED

Testing and surveillance are the first steps in staying ahead of mUM^2-5:

Don’t wait for symptoms. TESTING AND SURVEILLANCE should start early and be risk-informed.^2-5

Assist in shaping future care strategies with gene expression profiling AND PRAME TESTING^3-5

In addition to tumor size and location, the genetic profile offers important information that can help assess metastatic risk and support informed decisions about future treatment options.^2-4

GEP AND PRAME TESTING can inform risk-adjusted patient management.^3-5

When considering long-term treatment plans for UM patients at higher risk of metastasis, HLA testing may provide useful information.³ Genetic testing can determine treatment eligibility and support timely care decisions.³

HLA Status can be assessed by a blood test at any time.¹⁰

Risk stratification could help
empower precision imaging surveillance^3,11

Coordinated insight helps determine when and how to screen.²

All Eyes on Metastatic Risk in Uveal Melanoma
Hear leading ocular and medical oncologists discuss real-world approaches to risk assessment, surveillance, and long-term care in this expert roundtable series.